|
|
Blood, 1 November 2005, Vol. 106, No. 9, pp. 3035-3042.
Prepublished online as a Blood First Edition Paper on July 12, 2005; DOI 10.1182/blood-2005-03-1153.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B
Janine J. J. Hulstein,
Philip G. de Groot,
Karen Silence,
Agnès Veyradier,
Rob Fijnheer, and
Peter J. Lenting
From the Laboratory for Thrombosis and Haemostasis, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands; Ablynx, Ghent, Belgium; INSERM U143Le Kremlin-Bicêtre, France; and Jeroen Bosch Hospital, Location Groot Ziekengasthuis, Department of Internal Medicine, Den Bosch, The Netherlands.
Von Willebrand factor (VWF) is unable to interact spontaneously with platelets because this interaction requires a conversion of the VWF A1 domain into a glycoprotein Ib (GpIb) binding conformation. Here, we discuss a llama-derived antibody fragment (AU/VWFa-11) that specifically recognizes the GpIb-binding conformation. AU/VWFa-11 is unable to bind VWF in solution, but efficiently interacts with ristocetin- or botrocetin-activated VWF, VWF comprising type 2B mutation R1306Q, or immobilized VWF. These unique properties allowed us to use AU/VWFa-11 for the detection of activated VWF in plasma of patients characterized by spontaneous VWF-platelet interactions: von Willebrand disease (VWD) type 2B and thrombotic thrombocytopenic purpura (TTP). For VWD type 2B, levels of activated VWF were increased 12-fold (P < .001) compared to levels in healthy volunteers. An inverse correlation between activated VWF levels and platelet count was observed (R2 = 0.74; P < .003). With regard to TTP, a 2-fold (P < .001) increase in activated VWF levels was found in plasma of patients with acquired TTP, whereas an 8-fold increase (P < .003) was found in congenital TTP. No overlap in levels of activated VWF could be detected between acquired and congenital TTP, suggesting that AU/VWFa-11 could be used to distinguish between both disorders. Furthermore, it could provide a tool to investigate the role of VWF in the development of thrombocytopenia in various diseases.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B.-J. H. van den Born, N. V. van der Hoeven, E. Groot, P. J. Lenting, J. C.M. Meijers, M. Levi, and G. A. van Montfrans
Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension
Hypertension,
April 1, 2008;
51(4):
862 - 866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Faunce
Nanotechnology in Global Medicine and Human Biosecurity: Private Interests, Policy Dilemmas, and the Calibration of Public Health Law
J. Law Med. Ethics,
December 1, 2007;
35(4):
629 - 642.
[PDF]
|
|
|
|
|
|
|
J. J. J. Hulstein, P. J. Lenting, B. de Laat, R. H. W. M. Derksen, R. Fijnheer, and P. G. de Groot
{beta}2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation
Blood,
September 1, 2007;
110(5):
1483 - 1491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. M. Ruggeri and G. L. Mendolicchio
Adhesion Mechanisms in Platelet Function
Circ. Res.,
June 22, 2007;
100(12):
1673 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. M. van Schooten, C. V. Denis, T. Lisman, J. C. J. Eikenboom, F. W. Leebeek, J. Goudemand, E. Fressinaud, H. M. van den Berg, P. G. de Groot, and P. J. Lenting
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels
Blood,
March 15, 2007;
109(6):
2430 - 2437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Lenting, J. J. Hulstein, B. de Laat, R. H. Derksen, R. Fijnheer, and P. G. de Groot
Beta2-Glycoprotein I Interferes with von Willebrand Factor-Dependent Platelet Adhesion.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
415 - 415.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. B. Federici, L. Baronciani, M. T. Canciani, B. Moroni, C. Balduini, P. M. Mannucci, P. J. Lenting, and P. G. de Groot
Studies with the Nanobody That Detects the Gain-of-Function of von Willebrand Factor in a Cohort of Patients with Type 2B von Willebrand Disease: Correlation with Platelet Count, VWF Multimers and Molecular Defects.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
1011 - 1011.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Rothe, R. J. Hosse, and B. E. Power
In vitro display technologies reveal novel biopharmaceutics
FASEB J,
August 1, 2006;
20(10):
1599 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
